The aim of this study is to explore the expression of BAF250a protein in breast cancer and its association with the clinical and pathological characteristics and prognosis of breast cancer. The expression status of BAF250a protein was detected by Western blot analysis and immunohistochemical staining. The relationship between BAF250a proteins and clinicopathological parameters in 496 breast cancer specimens was analyzed. Western blot analysis showed that BAF250a protein had a lower expression in breast cancer specimens than in matched normal breast tissue (104.38 ± 11.65 vs. 55.94 ± 10.27; P = 0.004, t test). Among the 496 enrolled breast cancer patients, BAF250a protein expression was absent in 324 (65.3 %). Universal and multiple analyses indicated that BAF250a protein expression loss was significantly related to histological grade, metastatic nodes, tumor node metastasis (TNM) stage, and the expression of estrogen receptor (ER), progesterone receptor (PR), c-erbB-2, and p53 (all P < 0.05). For TNM stage, rank correlation coefficients were 0.199 and 0.191, respectively, (P < 0.05), but BAF250a protein deletion had either a positive or a negative correlation with ER, PR, c-erbB-2, and p53 protein expression (correlation coefficients were 0.231, 0.207, −0.098, −0.128; P < 0.05). Analysis of survival rates showed that the patients with BAF250a protein expression attained a significantly better postoperative disease-specific survival than those with BAF250a protein deletion (88.4 vs. 79.0 %; P = 0.003). In the Cox regression test, BAF250a protein deletion was detected as an independent prognostic factor (P = 0.014). BAF250a protein might be a new potential target for breast cancer treatment.
Breast cancer ARID1A BAF250a protein Prognostic factor Survival
This is a preview of subscription content, log in to check access.
This study was funded by the China National Natural Science Foundation (nos. 81102029 and 81172047).
Conflicts of interest
Dallas PB, Pacchione S, Wilsker D, Bowrin V, Kobayashi R, Moran E. The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol. 2000;20:3137–46.CrossRefPubMedPubMedCentralGoogle Scholar
Cornen S, Adelaide J, Bertucci F, et al. Mutations and deletions of ARID1A in breast tumors. Oncogene. 2012 Jan 16Google Scholar
Wang X, Nagl NG, Wilsker D, van Scoy M, Pacchione S, Yaciuk P, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J. 2004;383:319–25.CrossRefPubMedPubMedCentralGoogle Scholar
Wang Jr X, Nagl NG, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 2004;112:636.CrossRefPubMedGoogle Scholar
Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27.CrossRefPubMedPubMedCentralGoogle Scholar
Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosom Cancer. 2007;46:745–50.CrossRefPubMedGoogle Scholar
Wiegand KC et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328–33.CrossRefPubMedGoogle Scholar
Jones S, Wang TL, Shih I, Mao TL, Nakayama K, Roden R. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228–31.CrossRefPubMedPubMedCentralGoogle Scholar
Wang K, Kan J, Yuen ST. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–23.CrossRefPubMedGoogle Scholar
Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22(1):9–14.CrossRefPubMedPubMedCentralGoogle Scholar
Nagl Jr NG, Wang X, Patsialou A, et al. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J. 2007;26:752–63.CrossRefPubMedPubMedCentralGoogle Scholar
Nagl Jr NG, Patsialou A, Haines DS, Dallas PB, Beck GR, Moran E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005;65:9236–44.CrossRefPubMedGoogle Scholar
Hassan S et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. J Pathol. 2012;224:328–33.Google Scholar
Zhang X, Zhang Y, Yang Y, et al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol. 2012;36(3):288–93.CrossRefPubMedGoogle Scholar
Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem. 2002;277:22330–7.CrossRefPubMedGoogle Scholar
Oh J, Sohn DH, Ko M, Chung H, Jeon SH, Seong RH. BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem. 2008;283:11924–34.CrossRefPubMedGoogle Scholar
Xu Y, Yan W, Chen X. SNF5, a core component of the SWI/SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E. Oncogene. 2010;29:4090–100.CrossRefPubMedPubMedCentralGoogle Scholar
Nagl Jr NG, Zweitzig DR, Thimmapaya B, Beck Jr GR, Moran E. The cmyc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res. 2006;66:1289–93.CrossRefPubMedGoogle Scholar